Systemic treatment with interleukin-4 induces regression of pulmonary metastases in a murine renal cell carcinoma model.
Advanced metastatic renal cell carcinoma has been shown to be responsive to immunotherapy but the response rate is still limited. We have investigated the therapeutic potential of systemic interleukin-4 (IL-4) administration for the treatment of pulmonary metastases in the murine Renca renal adenocarcinoma model. Renca cells were injected iv in Balb/c mice to induce multiple pulmonary tumor nodules. From Day 5, Renca-bearing mice were treated with two daily injections of recombinant murine IL-4 for 5 consecutive days. IL-4 treatment induced a significant reduction in the number of lung metastases in a dose-dependent manner and significantly augmented the survival of treated animals. Immunohistochemistry studies, performed on lung sections, showed macrophage and CD8+ T cell infiltration in the tumor nodules 1 day after the end of IL-4 treatment. The CD8 infiltration increased by Day 7 after IL-4 treatment. Granulocyte infiltration was not detectable. To clarify further the role of the immune system in IL-4 anti-tumor effect, mice were depleted of lymphocyte subpopulations by in vivo injections of specific antibodies prior to treatment with IL-4. Depletion of CD8+ T cells or AsGM1+ cells abrogated the effect of IL-4 on lung metastases, whereas depletion of CD4+ T cells had no impact. These data indicate that CD8+ T cells and AsGM1+ cells are involved in IL-4-induced regression of established renal cell carcinoma.
Hillman
G G
GG
Department of Urology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA.
Younes
E
E
Visscher
D
D
Ali
E
E
Lam
J S
JS
Montecillo
E
E
Pontes
J E
JE
Haas
G P
GP
Puri
R K
RK
D000818:Animals; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D000950:Antigens, Ly / Q000032:analysis; D018414:CD8-Positive T-Lymphocytes / Q000473:pathology; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000517:prevention & control / Q000556:secondary* / Q000628:therapy; D005260:Female; D005677:G(M1) Ganglioside / Q000032:analysis; D007155:Immunologic Factors / Q000627:therapeutic use*; D015847:Interleukin-4 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000628:therapy*; D008175:Lung Neoplasms / Q000473:pathology / Q000517:prevention & control / Q000556:secondary*; D008212:Lymphocyte Depletion; D016131:Lymphocyte Subsets / Q000473:pathology; D016246:Lymphocytes, Tumor-Infiltrating / Q000473:pathology; D008264:Macrophages / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D011994:Recombinant Proteins / Q000627:therapeutic use; D018800:Thy-1 Antigens / Q000032:analysis; D013997:Time Factors
D000945:Antigens, Differentiation, T-Lymphocyte; D000950:Antigens, Ly; D007155:Immunologic Factors; D011994:Recombinant Proteins; D018800:Thy-1 Antigens; D015847:Interleukin-4; D005677:G(M1) Ganglioside; C018835:asialo GM1 ganglioside